Selected research
Industry Research
Zaleplon Industry Research Report 2026
Market perspective
The global Zaleplon market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Zaleplon is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Zaleplon is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Zaleplon is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Zaleplon include Teva Pharmaceuticals, Novartis, Mylan Pharmaceuticals, Pfizer, West Ward Pharmaceutical, Upsher Smith Laboratories, Unichem Laboratories, Roxane Laboratories and Orchid Healthcare Div Orchid Chemicals And Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Zaleplon market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Zaleplon Market by Company
Teva Pharmaceuticals
Novartis
Mylan Pharmaceuticals
Pfizer
West Ward Pharmaceutical
Upsher Smith Laboratories
Unichem Laboratories
Roxane Laboratories
Orchid Healthcare Div Orchid Chemicals And Pharmaceuticals
Hikma Pharms
Cipla
Aurobindo Pharma
Zaleplon Segment by Type
5mg
10mg
Zaleplon Segment by Application
Oral
Intranasal
Zaleplon Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Zaleplon market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Zaleplon and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Zaleplon.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Zaleplon manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Zaleplon by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Zaleplon in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 5mg
- 10mg
Applications
- Oral
- Intranasal
Companies covered
- Teva Pharmaceuticals
- Novartis
- Mylan Pharmaceuticals
- Pfizer
- West Ward Pharmaceutical
- Upsher Smith Laboratories
- Unichem Laboratories
- Roxane Laboratories
- Orchid Healthcare Div Orchid Chemicals And Pharmaceuticals
- Hikma Pharms
- Cipla
- Aurobindo Pharma
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Zaleplon Market Size (2021-2032)
- 2.2.2 Global Zaleplon Sales (2021-2032)
- 2.2.3 Global Zaleplon Market Average Price (2021-2032)
- 2.3 Zaleplon by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 5mg
- 2.3.3 10mg
- 2.4 Zaleplon by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Oral
- 2.4.3 Intranasal
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Zaleplon Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Zaleplon Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Zaleplon Revenue of Manufacturers (2021-2026)
- 3.4 Global Zaleplon Average Price by Manufacturers (2021-2026)
- 3.5 Global Zaleplon Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Zaleplon, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Zaleplon, Product Type & Application
- 3.8 Global Manufacturers of Zaleplon, Established Date
- 3.9 Global Zaleplon Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Teva Pharmaceuticals
- 4.1.1 Teva Pharmaceuticals Company Information
- 4.1.2 Teva Pharmaceuticals Business Overview
- 4.1.3 Teva Pharmaceuticals Zaleplon Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Teva Pharmaceuticals Zaleplon Product Portfolio
- 4.1.5 Teva Pharmaceuticals Recent Developments
- 4.2 Novartis
- 4.2.1 Novartis Company Information
- 4.2.2 Novartis Business Overview
- 4.2.3 Novartis Zaleplon Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Novartis Zaleplon Product Portfolio
- 4.2.5 Novartis Recent Developments
- 4.3 Mylan Pharmaceuticals
- 4.3.1 Mylan Pharmaceuticals Company Information
- 4.3.2 Mylan Pharmaceuticals Business Overview
- 4.3.3 Mylan Pharmaceuticals Zaleplon Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Mylan Pharmaceuticals Zaleplon Product Portfolio
- 4.3.5 Mylan Pharmaceuticals Recent Developments
- 4.4 Pfizer
- 4.4.1 Pfizer Company Information
- 4.4.2 Pfizer Business Overview
- 4.4.3 Pfizer Zaleplon Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Pfizer Zaleplon Product Portfolio
- 4.4.5 Pfizer Recent Developments
- 4.5 West Ward Pharmaceutical
- 4.5.1 West Ward Pharmaceutical Company Information
- 4.5.2 West Ward Pharmaceutical Business Overview
- 4.5.3 West Ward Pharmaceutical Zaleplon Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 West Ward Pharmaceutical Zaleplon Product Portfolio
- 4.5.5 West Ward Pharmaceutical Recent Developments
- 4.6 Upsher Smith Laboratories
- 4.6.1 Upsher Smith Laboratories Company Information
- 4.6.2 Upsher Smith Laboratories Business Overview
- 4.6.3 Upsher Smith Laboratories Zaleplon Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Upsher Smith Laboratories Zaleplon Product Portfolio
- 4.6.5 Upsher Smith Laboratories Recent Developments
- 4.7 Unichem Laboratories
- 4.7.1 Unichem Laboratories Company Information
- 4.7.2 Unichem Laboratories Business Overview
- 4.7.3 Unichem Laboratories Zaleplon Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Unichem Laboratories Zaleplon Product Portfolio
- 4.7.5 Unichem Laboratories Recent Developments
- 4.8 Roxane Laboratories
- 4.8.1 Roxane Laboratories Company Information
- 4.8.2 Roxane Laboratories Business Overview
- 4.8.3 Roxane Laboratories Zaleplon Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Roxane Laboratories Zaleplon Product Portfolio
- 4.8.5 Roxane Laboratories Recent Developments
- 4.9 Orchid Healthcare Div Orchid Chemicals And Pharmaceuticals
- 4.9.1 Orchid Healthcare Div Orchid Chemicals And Pharmaceuticals Company Information
- 4.9.2 Orchid Healthcare Div Orchid Chemicals And Pharmaceuticals Business Overview
- 4.9.3 Orchid Healthcare Div Orchid Chemicals And Pharmaceuticals Zaleplon Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Orchid Healthcare Div Orchid Chemicals And Pharmaceuticals Zaleplon Product Portfolio
- 4.9.5 Orchid Healthcare Div Orchid Chemicals And Pharmaceuticals Recent Developments
- 4.10 Hikma Pharms
- 4.10.1 Hikma Pharms Company Information
- 4.10.2 Hikma Pharms Business Overview
- 4.10.3 Hikma Pharms Zaleplon Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Hikma Pharms Zaleplon Product Portfolio
- 4.10.5 Hikma Pharms Recent Developments
- 4.11 Cipla
- 4.11.1 Cipla Company Information
- 4.11.2 Cipla Business Overview
- 4.11.3 Cipla Zaleplon Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Cipla Zaleplon Product Portfolio
- 4.11.5 Cipla Recent Developments
- 4.12 Aurobindo Pharma
- 4.12.1 Aurobindo Pharma Company Information
- 4.12.2 Aurobindo Pharma Business Overview
- 4.12.3 Aurobindo Pharma Zaleplon Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Aurobindo Pharma Zaleplon Product Portfolio
- 4.12.5 Aurobindo Pharma Recent Developments
5 Global Zaleplon Market Scenario by Region
- 5.1 Global Zaleplon Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Zaleplon Sales by Region: 2021-2032
- 5.2.1 Global Zaleplon Sales by Region: 2021-2026
- 5.2.2 Global Zaleplon Sales by Region: 2027-2032
- 5.3 Global Zaleplon Revenue by Region: 2021-2032
- 5.3.1 Global Zaleplon Revenue by Region: 2021-2026
- 5.3.2 Global Zaleplon Revenue by Region: 2027-2032
- 5.4 North America Zaleplon Market Facts & Figures by Country
- 5.4.1 North America Zaleplon Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Zaleplon Sales by Country (2021-2032)
- 5.4.3 North America Zaleplon Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Zaleplon Market Facts & Figures by Country
- 5.5.1 Europe Zaleplon Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Zaleplon Sales by Country (2021-2032)
- 5.5.3 Europe Zaleplon Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Zaleplon Market Facts & Figures by Country
- 5.6.1 Asia Pacific Zaleplon Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Zaleplon Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Zaleplon Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Zaleplon Market Facts & Figures by Country
- 5.7.1 South America Zaleplon Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Zaleplon Sales by Country (2021-2032)
- 5.7.3 South America Zaleplon Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Zaleplon Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Zaleplon Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Zaleplon Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Zaleplon Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Zaleplon Sales by Type (2021-2032)
- 6.1.1 Global Zaleplon Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Zaleplon Sales Market Share by Type (2021-2032)
- 6.2 Global Zaleplon Revenue by Type (2021-2032)
- 6.2.1 Global Zaleplon Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Zaleplon Revenue Market Share by Type (2021-2032)
- 6.3 Global Zaleplon Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Zaleplon Sales by Application (2021-2032)
- 7.1.1 Global Zaleplon Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Zaleplon Sales Market Share by Application (2021-2032)
- 7.2 Global Zaleplon Revenue by Application (2021-2032)
- 7.2.1 Global Zaleplon Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Zaleplon Revenue Market Share by Application (2021-2032)
- 7.3 Global Zaleplon Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Zaleplon Value Chain Analysis
- 8.1.1 Zaleplon Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Zaleplon Production Mode & Process
- 8.2 Zaleplon Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Zaleplon Distributors
- 8.2.3 Zaleplon Customers
9 Global Zaleplon Analyzing Market Dynamics
- 9.1 Zaleplon Industry Trends
- 9.2 Zaleplon Industry Drivers
- 9.3 Zaleplon Industry Opportunities and Challenges
- 9.4 Zaleplon Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst